Given that approximately two-thirds of US adults are overweight, it is important to understand how obesity affects AD risk, how it interacts with APOE4, and the extent to which its detrimental effects can be mitigated with therapeutics. This evidence concerns the gene APOE and obesity due to melanocortin 4 receptor deficiency.